A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2009-04

AUTHORS

Lorenzo Fornaro, G. Masi, S. Bursi, F. Loupakis, E. Vasile, A. Antonuzzo, S. Chiara, E. Pfanner, A. Di Paolo, G. Bocci, M. Del Tacca, A. Falcone

ABSTRACT

PURPOSE: The GONO-FOLFOXIRI regimen demonstrated higher activity and efficacy than FOLFIRI in metastatic colorectal cancer patients. The aim of this study was to determine the maximum tolerated dose of capecitabine, in substitution of 5-fluorouracil, combined with oxaliplatin and irinotecan and to evaluate the pharmacokinetics of the drugs. PATIENTS AND METHODS: We treated 15 patients with escalating doses of capecitabine (from day 1 to 7) and fixed doses of oxaliplatin (85 mg/m(2)) plus irinotecan (165 mg/m(2)) (both administered on day 1), repeated every 2 weeks. Pharmacokinetic analysis was performed on plasma samples collected at the first cycle of treatment. RESULTS: The maximum tolerated dose of capecitabine resulted 2,000 mg/m(2)/day, with diarrhea being the only dose-limiting toxicity. Large interpatient variability in the pharmacokinetic parameters of investigated drugs was observed. Results in terms of activity are promising. CONCLUSIONS: At the maximum tolerated dose of capecitabine of 2,000 mg/m(2)/day the combination is feasible with promising activity and deserves further investigations. More... »

PAGES

965-969

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00280-008-0840-5

DOI

http://dx.doi.org/10.1007/s00280-008-0840-5

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1008005289

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/18839174


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1115", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Pharmacology and Pharmaceutical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adolescent", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bone Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Camptothecin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Capecitabine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Colorectal Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Deoxycytidine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease-Free Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dose-Response Relationship, Drug", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Feasibility Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fluorouracil", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Liver Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lung Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lymphatic Metastasis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Maximum Tolerated Dose", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Staging", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Organoplatinum Compounds", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pleural Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Rate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Young Adult", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "name": [
            "Department of Oncology, Azienda USL6 of Livorno, Istituto Toscano Tumori, Viale Alfieri, 36, 57124, Livorno, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fornaro", 
        "givenName": "Lorenzo", 
        "id": "sg:person.01164506727.84", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01164506727.84"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Department of Oncology, Azienda USL6 of Livorno, Istituto Toscano Tumori, Viale Alfieri, 36, 57124, Livorno, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Masi", 
        "givenName": "G.", 
        "id": "sg:person.01062670207.83", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01062670207.83"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Department of Oncology, Azienda USL6 of Livorno, Istituto Toscano Tumori, Viale Alfieri, 36, 57124, Livorno, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bursi", 
        "givenName": "S.", 
        "id": "sg:person.01352001642.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01352001642.20"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Department of Oncology, Azienda USL6 of Livorno, Istituto Toscano Tumori, Viale Alfieri, 36, 57124, Livorno, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Loupakis", 
        "givenName": "F.", 
        "id": "sg:person.01175106504.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01175106504.32"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Department of Oncology, Azienda USL6 of Livorno, Istituto Toscano Tumori, Viale Alfieri, 36, 57124, Livorno, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Vasile", 
        "givenName": "E.", 
        "id": "sg:person.01006607213.66", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01006607213.66"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Day Hospital of Medical Oncology of Piombino, Azienda USL6 of Livorno, Istituto Toscano Tumori, Livorno, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Antonuzzo", 
        "givenName": "A.", 
        "id": "sg:person.01144410463.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01144410463.37"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ospedale San Martino", 
          "id": "https://www.grid.ac/institutes/grid.410345.7", 
          "name": [
            "Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chiara", 
        "givenName": "S.", 
        "id": "sg:person.01236567455.95", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01236567455.95"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Pisa", 
          "id": "https://www.grid.ac/institutes/grid.5395.a", 
          "name": [
            "Department of Oncology, Azienda Ospedaliero-Universitaria di Pisa, Istituto Toscano Tumori, Pisa, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pfanner", 
        "givenName": "E.", 
        "id": "sg:person.0736733622.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0736733622.31"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Pisa", 
          "id": "https://www.grid.ac/institutes/grid.5395.a", 
          "name": [
            "Division of Pharmacology and Chemotherapy, Department of Internal Medicine, University of Pisa, Pisa, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Di Paolo", 
        "givenName": "A.", 
        "id": "sg:person.01014555007.48", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01014555007.48"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Pisa", 
          "id": "https://www.grid.ac/institutes/grid.5395.a", 
          "name": [
            "Division of Pharmacology and Chemotherapy, Department of Internal Medicine, University of Pisa, Pisa, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bocci", 
        "givenName": "G.", 
        "id": "sg:person.01066531307.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01066531307.37"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Pisa", 
          "id": "https://www.grid.ac/institutes/grid.5395.a", 
          "name": [
            "Division of Pharmacology and Chemotherapy, Department of Internal Medicine, University of Pisa, Pisa, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Del Tacca", 
        "givenName": "M.", 
        "id": "sg:person.0101712630.89", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0101712630.89"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Pisa", 
          "id": "https://www.grid.ac/institutes/grid.5395.a", 
          "name": [
            "Department of Oncology, Azienda USL6 of Livorno, Istituto Toscano Tumori, Viale Alfieri, 36, 57124, Livorno, Italy", 
            "Department of Oncology, Transplants and New Technologies in Medicine, University of Pisa, Pisa, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Falcone", 
        "givenName": "A.", 
        "id": "sg:person.01006230145.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01006230145.44"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/s0731-7085(02)00151-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004992250"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2006.09.2684", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014958514"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdf089", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017678169"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdh470", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017702605"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(07)61086-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026311361"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2006.09.0928", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029306962"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-008-0754-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030608753", 
          "https://doi.org/10.1007/s00280-008-0754-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-008-0754-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030608753", 
          "https://doi.org/10.1007/s00280-008-0754-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0959-8049(01)00415-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031845533"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2004.11.037", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034270716"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdi227", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037535050"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdi227", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037535050"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/01.ftd.0000162016.11148.1b", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042696710"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/01.ftd.0000162016.11148.1b", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042696710"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/01.ftd.0000162016.11148.1b", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042696710"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdm347", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050358995"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2002.12.075", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064203208"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2003.09.016", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064203830"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2001.19.15.3456", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074857556"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2009-04", 
    "datePublishedReg": "2009-04-01", 
    "description": "PURPOSE: The GONO-FOLFOXIRI regimen demonstrated higher activity and efficacy than FOLFIRI in metastatic colorectal cancer patients. The aim of this study was to determine the maximum tolerated dose of capecitabine, in substitution of 5-fluorouracil, combined with oxaliplatin and irinotecan and to evaluate the pharmacokinetics of the drugs.\nPATIENTS AND METHODS: We treated 15 patients with escalating doses of capecitabine (from day 1 to 7) and fixed doses of oxaliplatin (85 mg/m(2)) plus irinotecan (165 mg/m(2)) (both administered on day 1), repeated every 2 weeks. Pharmacokinetic analysis was performed on plasma samples collected at the first cycle of treatment.\nRESULTS: The maximum tolerated dose of capecitabine resulted 2,000 mg/m(2)/day, with diarrhea being the only dose-limiting toxicity. Large interpatient variability in the pharmacokinetic parameters of investigated drugs was observed. Results in terms of activity are promising.\nCONCLUSIONS: At the maximum tolerated dose of capecitabine of 2,000 mg/m(2)/day the combination is feasible with promising activity and deserves further investigations.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s00280-008-0840-5", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1088364", 
        "issn": [
          "0344-5704", 
          "1432-0843"
        ], 
        "name": "Cancer Chemotherapy and Pharmacology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "5", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "63"
      }
    ], 
    "name": "A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer", 
    "pagination": "965-969", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "26235d7a8dac54660d39852d2888e63fbc9082a7556f6c2bcb1973a8ac2c055c"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "18839174"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "7806519"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00280-008-0840-5"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1008005289"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00280-008-0840-5", 
      "https://app.dimensions.ai/details/publication/pub.1008005289"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T00:15", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8695_00000510.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2Fs00280-008-0840-5"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00280-008-0840-5'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00280-008-0840-5'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00280-008-0840-5'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00280-008-0840-5'


 

This table displays all metadata directly associated to this object as RDF triples.

314 TRIPLES      21 PREDICATES      70 URIs      47 LITERALS      35 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00280-008-0840-5 schema:about N1f5bc13e8eb441549e303e70f7d64328
2 N23550172e8b5444096bf43f39df43aec
3 N25fe5c7d28164f85b8cf351220165f2e
4 N32823c9f8f784c33875f5be29decbed3
5 N36ba2db006d44e1793b977ed669578dd
6 N3b0e365910c44fa49171be564cb135c1
7 N3cef04133c0d4630832ebe4908c641f2
8 N433deb732fc9400e897670e53a261bed
9 N5a64c7b44a524d7b9390653f0a39729c
10 N5b2c707f12464031a7a6b661c5cbad6f
11 N64a7ff4a97e443cfb869e7496ea705b3
12 N77487bbeeb3a4b6595df47765abfc6fb
13 N7eb1cd8e48e04e9484e8f727c388ed06
14 N9d1518b3f91342cf9214db85d3dd34df
15 Na151bd1e732d47b7856d0b4b167dbcce
16 Na24df63d4e0a46c899e8c726ab1ce324
17 Na9486480a8a9478e849626aed5577136
18 Nc3fe5d9a08a94d49a087771806479eb3
19 Ncc4100cb53f34a9983fdc2b934894ca8
20 Nccbecb6815434582ba5fee2d89839012
21 Ndb740b18c5d94771880e008fdb192f82
22 Ndbaf2f167d064d5792f3966e5d7d3014
23 Ndbaf5ce7407244b2b12a46e0dc3ce3ff
24 Ne3dee24c499f4c6b992a4d3a0fd179a9
25 Nf30aabe7152747baa8f34674ab88984e
26 Nf84c62253bbf4f6b900edd25f64ae32f
27 anzsrc-for:11
28 anzsrc-for:1115
29 schema:author Na86fe64b87bd411089f9df23c92a7400
30 schema:citation sg:pub.10.1007/s00280-008-0754-2
31 https://doi.org/10.1016/s0140-6736(07)61086-1
32 https://doi.org/10.1016/s0731-7085(02)00151-6
33 https://doi.org/10.1016/s0959-8049(01)00415-4
34 https://doi.org/10.1093/annonc/mdf089
35 https://doi.org/10.1093/annonc/mdh470
36 https://doi.org/10.1093/annonc/mdi227
37 https://doi.org/10.1093/annonc/mdm347
38 https://doi.org/10.1097/01.ftd.0000162016.11148.1b
39 https://doi.org/10.1200/jco.2001.19.15.3456
40 https://doi.org/10.1200/jco.2002.12.075
41 https://doi.org/10.1200/jco.2003.09.016
42 https://doi.org/10.1200/jco.2004.11.037
43 https://doi.org/10.1200/jco.2006.09.0928
44 https://doi.org/10.1200/jco.2006.09.2684
45 schema:datePublished 2009-04
46 schema:datePublishedReg 2009-04-01
47 schema:description PURPOSE: The GONO-FOLFOXIRI regimen demonstrated higher activity and efficacy than FOLFIRI in metastatic colorectal cancer patients. The aim of this study was to determine the maximum tolerated dose of capecitabine, in substitution of 5-fluorouracil, combined with oxaliplatin and irinotecan and to evaluate the pharmacokinetics of the drugs. PATIENTS AND METHODS: We treated 15 patients with escalating doses of capecitabine (from day 1 to 7) and fixed doses of oxaliplatin (85 mg/m(2)) plus irinotecan (165 mg/m(2)) (both administered on day 1), repeated every 2 weeks. Pharmacokinetic analysis was performed on plasma samples collected at the first cycle of treatment. RESULTS: The maximum tolerated dose of capecitabine resulted 2,000 mg/m(2)/day, with diarrhea being the only dose-limiting toxicity. Large interpatient variability in the pharmacokinetic parameters of investigated drugs was observed. Results in terms of activity are promising. CONCLUSIONS: At the maximum tolerated dose of capecitabine of 2,000 mg/m(2)/day the combination is feasible with promising activity and deserves further investigations.
48 schema:genre research_article
49 schema:inLanguage en
50 schema:isAccessibleForFree false
51 schema:isPartOf N333118eb306849d4b906b6619e0c4147
52 N3a24fd6ba165443daf0da0f6576a40d1
53 sg:journal.1088364
54 schema:name A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer
55 schema:pagination 965-969
56 schema:productId N5ad567289b204e5cb743f49dc74255cd
57 N873b9fdd512a45f282c2460fc30913ef
58 N9a5bb80dac084cbe98c848bb81899d7a
59 Nc66e199238fe42759f2ad26b2a8c8976
60 Nedca62965c5c46eb90af67379981a83e
61 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008005289
62 https://doi.org/10.1007/s00280-008-0840-5
63 schema:sdDatePublished 2019-04-11T00:15
64 schema:sdLicense https://scigraph.springernature.com/explorer/license/
65 schema:sdPublisher Nbe678282993a4125bf1c8ef3a6ae8c4f
66 schema:url http://link.springer.com/10.1007%2Fs00280-008-0840-5
67 sgo:license sg:explorer/license/
68 sgo:sdDataset articles
69 rdf:type schema:ScholarlyArticle
70 N09a8a5a883514dc6817104bcbf80ccc0 schema:name Department of Oncology, Azienda USL6 of Livorno, Istituto Toscano Tumori, Viale Alfieri, 36, 57124, Livorno, Italy
71 rdf:type schema:Organization
72 N09c4fd1a2f614b1db2a5fa2bb11a8ee2 rdf:first sg:person.01062670207.83
73 rdf:rest Nb1a88f1ac5c04684adff7c431c1f49c8
74 N1f5bc13e8eb441549e303e70f7d64328 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
75 schema:name Neoplasm Staging
76 rdf:type schema:DefinedTerm
77 N23550172e8b5444096bf43f39df43aec schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
78 schema:name Bone Neoplasms
79 rdf:type schema:DefinedTerm
80 N25fe5c7d28164f85b8cf351220165f2e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
81 schema:name Adolescent
82 rdf:type schema:DefinedTerm
83 N289b30f41cef4669a620dabd823be986 schema:name Department of Oncology, Azienda USL6 of Livorno, Istituto Toscano Tumori, Viale Alfieri, 36, 57124, Livorno, Italy
84 rdf:type schema:Organization
85 N32823c9f8f784c33875f5be29decbed3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
86 schema:name Pleural Neoplasms
87 rdf:type schema:DefinedTerm
88 N333118eb306849d4b906b6619e0c4147 schema:issueNumber 5
89 rdf:type schema:PublicationIssue
90 N36ba2db006d44e1793b977ed669578dd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
91 schema:name Colorectal Neoplasms
92 rdf:type schema:DefinedTerm
93 N3a24fd6ba165443daf0da0f6576a40d1 schema:volumeNumber 63
94 rdf:type schema:PublicationVolume
95 N3b0e365910c44fa49171be564cb135c1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
96 schema:name Maximum Tolerated Dose
97 rdf:type schema:DefinedTerm
98 N3cef04133c0d4630832ebe4908c641f2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
99 schema:name Dose-Response Relationship, Drug
100 rdf:type schema:DefinedTerm
101 N433deb732fc9400e897670e53a261bed schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
102 schema:name Survival Rate
103 rdf:type schema:DefinedTerm
104 N5a64c7b44a524d7b9390653f0a39729c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
105 schema:name Female
106 rdf:type schema:DefinedTerm
107 N5ad567289b204e5cb743f49dc74255cd schema:name nlm_unique_id
108 schema:value 7806519
109 rdf:type schema:PropertyValue
110 N5b2c707f12464031a7a6b661c5cbad6f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Fluorouracil
112 rdf:type schema:DefinedTerm
113 N5e716890647c4cceaa7e3faddf7b584b rdf:first sg:person.01144410463.37
114 rdf:rest Ne426ef8f08ce41998f157d98a597f177
115 N6153860b2d054eae91048af8ff34d8ba rdf:first sg:person.01175106504.32
116 rdf:rest N9d5ab5a7adfd4a82b4baf61f313e891a
117 N64a7ff4a97e443cfb869e7496ea705b3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Liver Neoplasms
119 rdf:type schema:DefinedTerm
120 N77487bbeeb3a4b6595df47765abfc6fb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Disease-Free Survival
122 rdf:type schema:DefinedTerm
123 N7eb1cd8e48e04e9484e8f727c388ed06 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Feasibility Studies
125 rdf:type schema:DefinedTerm
126 N7f2c8c8c496b42b1bf1063355bd3f36d schema:name Day Hospital of Medical Oncology of Piombino, Azienda USL6 of Livorno, Istituto Toscano Tumori, Livorno, Italy
127 rdf:type schema:Organization
128 N873b9fdd512a45f282c2460fc30913ef schema:name dimensions_id
129 schema:value pub.1008005289
130 rdf:type schema:PropertyValue
131 N929c1e4c9c9948098ea3c01ddc737670 rdf:first sg:person.01014555007.48
132 rdf:rest Nd8fe70de0248498397435a2d8c5b4361
133 N980f2b7dce2f46d6bbe2f5c48dd57a32 schema:name Department of Oncology, Azienda USL6 of Livorno, Istituto Toscano Tumori, Viale Alfieri, 36, 57124, Livorno, Italy
134 rdf:type schema:Organization
135 N9a5bb80dac084cbe98c848bb81899d7a schema:name doi
136 schema:value 10.1007/s00280-008-0840-5
137 rdf:type schema:PropertyValue
138 N9d1518b3f91342cf9214db85d3dd34df schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Lymphatic Metastasis
140 rdf:type schema:DefinedTerm
141 N9d5ab5a7adfd4a82b4baf61f313e891a rdf:first sg:person.01006607213.66
142 rdf:rest N5e716890647c4cceaa7e3faddf7b584b
143 Na151bd1e732d47b7856d0b4b167dbcce schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Aged
145 rdf:type schema:DefinedTerm
146 Na24df63d4e0a46c899e8c726ab1ce324 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Young Adult
148 rdf:type schema:DefinedTerm
149 Na86fe64b87bd411089f9df23c92a7400 rdf:first sg:person.01164506727.84
150 rdf:rest N09c4fd1a2f614b1db2a5fa2bb11a8ee2
151 Na9486480a8a9478e849626aed5577136 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Treatment Outcome
153 rdf:type schema:DefinedTerm
154 Nb1a88f1ac5c04684adff7c431c1f49c8 rdf:first sg:person.01352001642.20
155 rdf:rest N6153860b2d054eae91048af8ff34d8ba
156 Nb60de9a6fd284706bca36013890a7ad6 rdf:first sg:person.01006230145.44
157 rdf:rest rdf:nil
158 Nbccb96f94ba04b829e5d884ac740f545 rdf:first sg:person.0736733622.31
159 rdf:rest N929c1e4c9c9948098ea3c01ddc737670
160 Nbe678282993a4125bf1c8ef3a6ae8c4f schema:name Springer Nature - SN SciGraph project
161 rdf:type schema:Organization
162 Nc3fe5d9a08a94d49a087771806479eb3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Capecitabine
164 rdf:type schema:DefinedTerm
165 Nc66e199238fe42759f2ad26b2a8c8976 schema:name pubmed_id
166 schema:value 18839174
167 rdf:type schema:PropertyValue
168 Ncc4100cb53f34a9983fdc2b934894ca8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
169 schema:name Camptothecin
170 rdf:type schema:DefinedTerm
171 Nccbecb6815434582ba5fee2d89839012 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
172 schema:name Middle Aged
173 rdf:type schema:DefinedTerm
174 Nd3fa98999d754f00b2d7dbbcc84a934c schema:name Department of Oncology, Azienda USL6 of Livorno, Istituto Toscano Tumori, Viale Alfieri, 36, 57124, Livorno, Italy
175 rdf:type schema:Organization
176 Nd8fe70de0248498397435a2d8c5b4361 rdf:first sg:person.01066531307.37
177 rdf:rest Ne31529903cb348b7b2500f9879a4332a
178 Ndb740b18c5d94771880e008fdb192f82 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name Humans
180 rdf:type schema:DefinedTerm
181 Ndbaf2f167d064d5792f3966e5d7d3014 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Organoplatinum Compounds
183 rdf:type schema:DefinedTerm
184 Ndbaf5ce7407244b2b12a46e0dc3ce3ff schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
185 schema:name Adult
186 rdf:type schema:DefinedTerm
187 Nde45a856f3394eeeb0de91e72218d2e1 schema:name Department of Oncology, Azienda USL6 of Livorno, Istituto Toscano Tumori, Viale Alfieri, 36, 57124, Livorno, Italy
188 rdf:type schema:Organization
189 Ne31529903cb348b7b2500f9879a4332a rdf:first sg:person.0101712630.89
190 rdf:rest Nb60de9a6fd284706bca36013890a7ad6
191 Ne3dee24c499f4c6b992a4d3a0fd179a9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
192 schema:name Antineoplastic Combined Chemotherapy Protocols
193 rdf:type schema:DefinedTerm
194 Ne426ef8f08ce41998f157d98a597f177 rdf:first sg:person.01236567455.95
195 rdf:rest Nbccb96f94ba04b829e5d884ac740f545
196 Nedca62965c5c46eb90af67379981a83e schema:name readcube_id
197 schema:value 26235d7a8dac54660d39852d2888e63fbc9082a7556f6c2bcb1973a8ac2c055c
198 rdf:type schema:PropertyValue
199 Nf30aabe7152747baa8f34674ab88984e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
200 schema:name Deoxycytidine
201 rdf:type schema:DefinedTerm
202 Nf84c62253bbf4f6b900edd25f64ae32f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
203 schema:name Lung Neoplasms
204 rdf:type schema:DefinedTerm
205 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
206 schema:name Medical and Health Sciences
207 rdf:type schema:DefinedTerm
208 anzsrc-for:1115 schema:inDefinedTermSet anzsrc-for:
209 schema:name Pharmacology and Pharmaceutical Sciences
210 rdf:type schema:DefinedTerm
211 sg:journal.1088364 schema:issn 0344-5704
212 1432-0843
213 schema:name Cancer Chemotherapy and Pharmacology
214 rdf:type schema:Periodical
215 sg:person.01006230145.44 schema:affiliation https://www.grid.ac/institutes/grid.5395.a
216 schema:familyName Falcone
217 schema:givenName A.
218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01006230145.44
219 rdf:type schema:Person
220 sg:person.01006607213.66 schema:affiliation Nde45a856f3394eeeb0de91e72218d2e1
221 schema:familyName Vasile
222 schema:givenName E.
223 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01006607213.66
224 rdf:type schema:Person
225 sg:person.01014555007.48 schema:affiliation https://www.grid.ac/institutes/grid.5395.a
226 schema:familyName Di Paolo
227 schema:givenName A.
228 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01014555007.48
229 rdf:type schema:Person
230 sg:person.0101712630.89 schema:affiliation https://www.grid.ac/institutes/grid.5395.a
231 schema:familyName Del Tacca
232 schema:givenName M.
233 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0101712630.89
234 rdf:type schema:Person
235 sg:person.01062670207.83 schema:affiliation N09a8a5a883514dc6817104bcbf80ccc0
236 schema:familyName Masi
237 schema:givenName G.
238 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01062670207.83
239 rdf:type schema:Person
240 sg:person.01066531307.37 schema:affiliation https://www.grid.ac/institutes/grid.5395.a
241 schema:familyName Bocci
242 schema:givenName G.
243 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01066531307.37
244 rdf:type schema:Person
245 sg:person.01144410463.37 schema:affiliation N7f2c8c8c496b42b1bf1063355bd3f36d
246 schema:familyName Antonuzzo
247 schema:givenName A.
248 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01144410463.37
249 rdf:type schema:Person
250 sg:person.01164506727.84 schema:affiliation Nd3fa98999d754f00b2d7dbbcc84a934c
251 schema:familyName Fornaro
252 schema:givenName Lorenzo
253 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01164506727.84
254 rdf:type schema:Person
255 sg:person.01175106504.32 schema:affiliation N980f2b7dce2f46d6bbe2f5c48dd57a32
256 schema:familyName Loupakis
257 schema:givenName F.
258 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01175106504.32
259 rdf:type schema:Person
260 sg:person.01236567455.95 schema:affiliation https://www.grid.ac/institutes/grid.410345.7
261 schema:familyName Chiara
262 schema:givenName S.
263 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01236567455.95
264 rdf:type schema:Person
265 sg:person.01352001642.20 schema:affiliation N289b30f41cef4669a620dabd823be986
266 schema:familyName Bursi
267 schema:givenName S.
268 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01352001642.20
269 rdf:type schema:Person
270 sg:person.0736733622.31 schema:affiliation https://www.grid.ac/institutes/grid.5395.a
271 schema:familyName Pfanner
272 schema:givenName E.
273 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0736733622.31
274 rdf:type schema:Person
275 sg:pub.10.1007/s00280-008-0754-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030608753
276 https://doi.org/10.1007/s00280-008-0754-2
277 rdf:type schema:CreativeWork
278 https://doi.org/10.1016/s0140-6736(07)61086-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026311361
279 rdf:type schema:CreativeWork
280 https://doi.org/10.1016/s0731-7085(02)00151-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004992250
281 rdf:type schema:CreativeWork
282 https://doi.org/10.1016/s0959-8049(01)00415-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031845533
283 rdf:type schema:CreativeWork
284 https://doi.org/10.1093/annonc/mdf089 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017678169
285 rdf:type schema:CreativeWork
286 https://doi.org/10.1093/annonc/mdh470 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017702605
287 rdf:type schema:CreativeWork
288 https://doi.org/10.1093/annonc/mdi227 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037535050
289 rdf:type schema:CreativeWork
290 https://doi.org/10.1093/annonc/mdm347 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050358995
291 rdf:type schema:CreativeWork
292 https://doi.org/10.1097/01.ftd.0000162016.11148.1b schema:sameAs https://app.dimensions.ai/details/publication/pub.1042696710
293 rdf:type schema:CreativeWork
294 https://doi.org/10.1200/jco.2001.19.15.3456 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074857556
295 rdf:type schema:CreativeWork
296 https://doi.org/10.1200/jco.2002.12.075 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064203208
297 rdf:type schema:CreativeWork
298 https://doi.org/10.1200/jco.2003.09.016 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064203830
299 rdf:type schema:CreativeWork
300 https://doi.org/10.1200/jco.2004.11.037 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034270716
301 rdf:type schema:CreativeWork
302 https://doi.org/10.1200/jco.2006.09.0928 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029306962
303 rdf:type schema:CreativeWork
304 https://doi.org/10.1200/jco.2006.09.2684 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014958514
305 rdf:type schema:CreativeWork
306 https://www.grid.ac/institutes/grid.410345.7 schema:alternateName Ospedale San Martino
307 schema:name Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
308 rdf:type schema:Organization
309 https://www.grid.ac/institutes/grid.5395.a schema:alternateName University of Pisa
310 schema:name Department of Oncology, Azienda Ospedaliero-Universitaria di Pisa, Istituto Toscano Tumori, Pisa, Italy
311 Department of Oncology, Azienda USL6 of Livorno, Istituto Toscano Tumori, Viale Alfieri, 36, 57124, Livorno, Italy
312 Department of Oncology, Transplants and New Technologies in Medicine, University of Pisa, Pisa, Italy
313 Division of Pharmacology and Chemotherapy, Department of Internal Medicine, University of Pisa, Pisa, Italy
314 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...